Patrick M. Forde

18.8k total citations · 6 hit papers
186 papers, 5.7k citations indexed

About

Patrick M. Forde is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Patrick M. Forde has authored 186 papers receiving a total of 5.7k indexed citations (citations by other indexed papers that have themselves been cited), including 132 papers in Oncology, 108 papers in Pulmonary and Respiratory Medicine and 28 papers in Cancer Research. Recurrent topics in Patrick M. Forde's work include Cancer Immunotherapy and Biomarkers (104 papers), Lung Cancer Treatments and Mutations (63 papers) and Lung Cancer Diagnosis and Treatment (32 papers). Patrick M. Forde is often cited by papers focused on Cancer Immunotherapy and Biomarkers (104 papers), Lung Cancer Treatments and Mutations (63 papers) and Lung Cancer Diagnosis and Treatment (32 papers). Patrick M. Forde collaborates with scholars based in United States, Canada and Spain. Patrick M. Forde's co-authors include Julie R. Brahmer, Jarushka Naidoo, Evan J. Lipson, David S. Ettinger, Kristen A. Marrone, Suzanne L. Topalian, Ronan J. Kelly, Leisha A. Emens, Janis M. Taube and Christine L. Hann and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Medicine and Nature Communications.

In The Last Decade

Patrick M. Forde

176 papers receiving 5.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non–Small Cell Lung Cancer

2020 320 citations Jiajia Zhang, Patrick M. Forde et al. profile →
Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors

2021 257 citations Giuseppe Curigliano, Hans Gelderblom et al. Clinical Cancer Research profile →
Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy

2023 153 citations Suzanne L. Topalian, Patrick M. Forde et al. profile →
Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges

2023 105 citations Patrick M. Forde et al. profile →
Neoadjuvant Chemoimmunotherapy for NSCLC

2024 89 citations Patrick M. Forde, Tina Cascone et al. profile →
Clinical development of immuno-oncology therapeutics

2025 15 citations Jianxin Wang, Qi Shan et al. Cancer Letters profile →

Peers

Countries citing papers authored by Patrick M. Forde

Since Specialization

Citations

This map shows the geographic impact of Patrick M. Forde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick M. Forde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick M. Forde more than expected).

Fields of papers citing papers by Patrick M. Forde

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick M. Forde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick M. Forde. The network helps show where Patrick M. Forde may publish in the future.

Co-authorship network of co-authors of Patrick M. Forde

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick M. Forde. A scholar is included among the top collaborators of Patrick M. Forde based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick M. Forde. Patrick M. Forde is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clinical development of immuno-oncology therapeutics breakdown → 2025 ·Cancer Letters ·Jianxin Wang, (unknown), Qi Shan, Tingbo Liang, Patrick M. Forde, Lei Zheng	15
2	Higher levels of VEGF-A and TNFα in patients with immune checkpoint inhibitor-induced inflammatory arthritis 2025 ·Arthritis Research & Therapy ·Elise Gray-Gaillard, Ami A. Shah, Clifton O. Bingham, Jennifer H. Elisseeff, Joseph C. Murray, Julie R. Brahmer, Patrick M. Forde, Valsamo Anagnostou, Jennifer S. Mammen, Laura C. Cappelli	2
3	Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with resectable NSCLC: 4-year update from CheckMate 816. 2024 ·Journal of Clinical Oncology ·Jonathan Spicer, Nicolas Girard, Mariano Provencio, Changli Wang, Tetsuya Mitsudomi, Mark M. Awad, Everett E. Vokes, Janis M. Taube, Lorena Lupinacci, Gene Saylors, Fumihiro Tanaka, Moïshe Liberman, Sung Yong Lee, Aurelia Alexandru, M. D’Arcangelo, Phuong Tran, Javed Mahmood, (unknown), (unknown), Patrick M. Forde	25
4	Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC 2024 ·Journal of Thoracic Oncology ·(unknown), Robert B. Cameron, A. Esposito, (unknown), Luca Porcu, (unknown), Giuseppe Viscardi, Roberto Ferrara, Giulia Veronesi, Patrick M. Forde, Janis M. Taube, Everett E. Vokes, Christine M. Bestvina, James M. Dolezal, Matteo Antonio Sacco, Marta Monteforte, Tina Cascone, Marina Chiara Garassino, Valter Torri	23
5	Neoadjuvant immune checkpoint inhibitor therapy in resectable non-small cell lung cancer 2023 ·Lung Cancer ·(unknown), (unknown), Patrick M. Forde	9
6	Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer 2023 ·Clinical Cancer Research ·Samuel Rosner, Joshua E. Reuss, Marianna Zahurak, Jiajia Zhang, (unknown), Janis M. Taube, Valsamo Anagnostou, Kellie N. Smith, Joanne Riemer, Peter B. Illei, Stephen Broderick, David R. Jones, Suzanne L. Topalian, Drew M. Pardoll, Julie R. Brahmer, Jamie E. Chaft, Patrick M. Forde	44
7	1261O Neoadjuvant nivolumab (N) + ipilimumab (I) vs chemotherapy (C) in the phase III CheckMate 816 trial 2023 ·Annals of Oncology ·Mark M. Awad, Patrick M. Forde, Nicolas Girard, (unknown), (unknown), Shun Lü, (unknown), Enriqueta Felip, Stephen Broderick, Scott J. Swanson, (unknown), Keith M. Kerr, (unknown), (unknown), (unknown), Javed Mahmood, (unknown), David Balli, Nan Hu, Mariano Provencio	14
8	Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer 2023 ·BioDrugs ·Khaled Sanber, Samuel Rosner, Patrick M. Forde, Kristen A. Marrone	4
9	Translating the evolving molecular landscape of tumors to biomarkers of response for cancer immunotherapy 2022 ·Science Translational Medicine ·Valsamo Anagnostou, (unknown), Jamie E. Medina, Patrick M. Forde, Victor E. Velculescu	29
10	Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors breakdown → 2021 ·Clinical Cancer Research ·Giuseppe Curigliano, Hans Gelderblom, Nicolas Mach, Toshihiko Doi, David Tai, Patrick M. Forde, John Sarantopoulos, Philippe L. Bédard, Chia‐Chi Lin, F. Stephen Hodi, Sofie Wilgenhof, Armando Santoro, Catherine Sabatos-Peyton, Tyler A. Longmire, Alexandros Xyrafas, Haiying Sun, Sabine Gutzwiller, Luigi Manenti, Aung Naing	257
11	Association of severe lymphopenia and disease progression in unresectable locally advanced non-small cell lung cancer treated with definitive chemoradiation and immunotherapy 2021 ·Lung Cancer ·(unknown), (unknown), (unknown), Laura Prichett, Julie R. Brahmer, Patrick M. Forde, (unknown), Kristen A. Marrone, Vincent K. Lam, Christine L. Hann, Stephen Broderick, Richard J. Battafarano, Jinny S. Ha, Errol L. Bush, Stephen C. Yang, (unknown), Josephine Feliciano	38
12	Radiation Versus Immune Checkpoint Inhibitor Associated Pneumonitis: Distinct Radiologic Morphologies 2021 ·The Oncologist ·Xuguang Chen, Khadija Sheikh, Erica C. Nakajima, Cheng Ting Lin, Junghoon Lee, Chen Hu, Russell K. Hales, Patrick M. Forde, Jarushka Naidoo, Khinh Ranh Voong	39
13	Consolidative Radiotherapy in Oligometastatic Lung Cancer: Patient Selection With a Prediction Nomogram 2020 ·Clinical Lung Cancer ·(unknown), (unknown), Sarah Z. Hazell, Wei Fu, Peijin Han, Michael R. Bowers, Benjamin Levy, Patrick M. Forde, (unknown), Russell K. Hales	8
14	Isolated progression of metastatic lung cancer: Clinical outcomes associated with definitive radiotherapy 2020 ·Cancer ·(unknown), (unknown), Wei Fu, Chen Hu, Sarah Z. Hazell, Peijin Han, Todd McNutt, Patrick M. Forde, Kristin J. Redmond, Khinh Ranh Voong, Russell K. Hales	11
15	Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade 2019 ·Clinical Cancer Research ·Julie E. Stein, Evan J. Lipson, Tricia R. Cottrell, Patrick M. Forde, Robert A. Anders, Ashley Cimino‐Mathews, Elizabeth D. Thompson, Mohamad E. Allaf, Mark Yarchoan, Josephine Feliciano, Hao Wang, Elizabeth M. Jaffee, Drew M. Pardoll, Suzanne L. Topalian, Janis M. Taube	92
16	The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity 2018 ·Cancer Immunology Research ·Ludmila Danilova, Valsamo Anagnostou, Justina X. Caushi, John-William Sidhom, Haidan Guo, Hok Yee Chan, Prerna Suri, Ada Tam, Jiajia Zhang, Margueritta El Asmar, Kristen A. Marrone, Jarushka Naidoo, Julie R. Brahmer, Patrick M. Forde, Alexander S. Baras, Leslie Cope, Victor E. Velculescu, Drew M. Pardoll, Franck Housseau, Kellie N. Smith	99
17	Early Noninvasive Detection of Response to Targeted Therapy in Non–Small Cell Lung Cancer 2018 ·Cancer Research ·Jillian Phallen, Alessandro Leal, Brian Woodward, Patrick M. Forde, Jarushka Naidoo, Kristen A. Marrone, Julie R. Brahmer, Jacob Fiksel, Jamie E. Medina, Stephen Cristiano, Doreen N. Palsgrove, Christopher D. Gocke, Daniel C. Bruhm, (unknown), Vilmos Adleff, Elizabeth Weihe, Valsamo Anagnostou, Robert B. Scharpf, Victor E. Velculescu, Hatim Husain	73
18	Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer 2018 ·Lung Cancer ·Leora Horn, Joshua Bauml, Patrick M. Forde, Keith L. Davis, Nathaniel J. Myall, Medha Sasané, Anand A. Dalal, (unknown), Antoinette J. Wozniak, Christina S. Baik, Alex Mutebi, Pingkuan Zhang, Heather A. Wakelee, Bruce E. Johnson	12
19	Effect of Antioxidants on Salt-Induced Hypertension and Renal Dysfunction. 2000 ·Hypertension ·María R. Trolliet, Patrick M. Forde, Murray A. Rudd, Joseph Loscalzo	1
20	Pregnancy associated with uterine abnormality. 1978 ·Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) ·Patrick M. Forde, (unknown), (unknown)	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact